Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Aldesleukin + Dinutuximab beta |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Aldesleukin | Proleukin | IL-2|Interleukin-2|IL2 | Aldesleukin (IL-2) is a cytokine that potentially modulates antitumor immune response (NCI Drug Dictionary). | |
| Dinutuximab beta | ch14.18/CHO|APN311|APN-311|APN 311|Qarziba | GD2 Antibody 6 | Dinutuximab beta (ch14.18/CHO) is biosimilar of the anti-GD2 antibody Unituxin (dinutuximab) produced in CHO cells, with a different glycosylation pattern than dinutuximab, which potentially induces antibody-dependent and complement-dependent cytotoxicity against GD2-expressing tumor cells, and reduces liver metastasis (PMID: 30613134, PMID: 15950727). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01704716 | Phase III | Busulfan + Melphalan Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Filgrastim Cisplatin + Cyclophosphamide + Doxorubicin + Etoposide + Vincristine Sulfate Dinutuximab beta Aldesleukin + Dinutuximab beta Carboplatin + Etoposide + Melphalan Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Vincristine Sulfate | High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN) | Recruiting | SWE | SVN | SVK | POL | NOR | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DNK | CZE | CHE | BEL | AUT | AUS | 1 |
CKB BOOST